VYTRUS BIOTECH EO -01 Cash Flow-to-Debt Ratio
VYTRUS BIOTECH EO -01 cash flow-to-debt ratio. VYTRUS BIOTECH EO -01 (V5P) has a Cash Flow-to-Debt Ratio of 0.90x as of December 2025, meaning its operating cash flow of €3.90 Million could theoretically repay 1% of its total liabilities (€4.35 Million) in one year. Check V5P cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of VYTRUS BIOTECH EO -01 (2021–2025)
Cash flow-to-debt ratio of VYTRUS BIOTECH EO -01 from 2021 to 2025. Historical debt coverage capacity for VYTRUS BIOTECH EO -01 across 5 annual periods. Check VYTRUS BIOTECH EO -01 (V5P) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
VYTRUS BIOTECH EO -01 Cash Flow-to-Debt Ratio by Year (2021–2025)
VYTRUS BIOTECH EO -01 cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for VYTRUS BIOTECH EO -01. For the full cash flow conversion analysis, see VYTRUS BIOTECH EO -01 operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.90x | €3.90 Million | €4.35 Million | ▲ +86.5% |
| 2024 | 0.48x | €1.84 Million | €3.84 Million | ▲ +113.6% |
| 2023 | 0.22x | €904.39K | €4.02 Million | ▼ -28.8% |
| 2022 | 0.32x | €1.03 Million | €3.25 Million | ▲ +106.6% |
| 2021 | 0.15x | €447.92K | €2.93 Million | — |